Phibro Animal Health (NASDAQ:PAHC) CEO Jack Bendheim Sells 1,235 Shares

January 28, 2026 by InsiderTrades.com

Key Points

CEO Jack Bendheim has been actively selling stock: he sold 1,235 shares on Jan. 23 at $40.55 and, together with multiple sales in December–January, has sold roughly $2.23 million of PAHC stock, leaving him with 15,445 shares after the latest transaction.
Recent results and guidance were positive: Phibro beat Q results (EPS $0.73 vs. $0.58 consensus; revenue $363.9M vs. $345.4M) and set FY2026 guidance of $2.64–$2.81 EPS, while paying a $0.12 quarterly dividend (≈1.2% yield).
Market and analyst picture is mixed: the stock trades with a $1.6B market cap and a 23.8x PE, has a 1‑year range of $16.16–$46.42, and faces divergent analyst views (JPMorgan raised its target to $50/overweight, while the MarketBeat average rating is "Hold" with a $31.40 target).

Phibro Animal Health Corporation (NASDAQ:PAHC - Get Free Report) CEO Jack Bendheim sold 1,235 shares of Phibro Animal Health stock in a transaction dated Friday, January 23rd. The stock was sold at an average price of $40.55, for a total value of $50,079.25. Following the completion of the transaction, the chief executive officer owned 15,445 shares of the company's stock, valued at approximately $626,294.75. This represents a 7.40% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Jack Bendheim also recently made the following trade(s):

On Thursday, January 22nd, Jack Bendheim sold 13,158 shares of Phibro Animal Health stock. The shares were sold at an average price of $41.98, for a total value of $552,372.84.
On Wednesday, January 21st, Jack Bendheim sold 14,687 shares of Phibro Animal Health stock. The shares were sold at an average price of $41.68, for a total value of $612,154.16.
On Thursday, January 15th, Jack Bendheim sold 2,932 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.02, for a total value of $117,338.64.
On Wednesday, January 14th, Jack Bendheim sold 3,651 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.53, for a total value of $147,975.03.
On Tuesday, January 13th, Jack Bendheim sold 7,551 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.32, for a total transaction of $304,456.32.
On Friday, January 9th, Jack Bendheim sold 213 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.16, for a total transaction of $8,554.08.
On Wednesday, January 7th, Jack Bendheim sold 328 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.09, for a total transaction of $13,149.52.
On Thursday, December 11th, Jack Bendheim sold 5,752 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.93, for a total transaction of $235,429.36.
On Tuesday, December 9th, Jack Bendheim sold 1,288 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.19, for a total transaction of $51,764.72.
On Monday, December 8th, Jack Bendheim sold 3,520 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.06, for a total transaction of $141,011.20.

Phibro Animal Health Stock Up 0.1%

Shares of NASDAQ:PAHC opened at $39.52 on Wednesday. The firm has a market capitalization of $1.60 billion, a PE ratio of 23.81, a price-to-earnings-growth ratio of 1.12 and a beta of 0.79. The business has a 50 day simple moving average of $39.97 and a two-hundred day simple moving average of $37.69. Phibro Animal Health Corporation has a 1 year low of $16.16 and a 1 year high of $46.42. The company has a debt-to-equity ratio of 2.32, a current ratio of 3.09 and a quick ratio of 1.35.

Phibro Animal Health (NASDAQ:PAHC - Get Free Report) last issued its quarterly earnings results on Wednesday, November 5th. The company reported $0.73 earnings per share for the quarter, topping the consensus estimate of $0.58 by $0.15. Phibro Animal Health had a return on equity of 36.26% and a net margin of 4.85%.The firm had revenue of $363.89 million for the quarter, compared to the consensus estimate of $345.44 million. Phibro Animal Health has set its FY 2026 guidance at 2.640-2.810 EPS. On average, equities analysts predict that Phibro Animal Health Corporation will post 1.95 EPS for the current year.

Phibro Animal Health Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, December 17th. Stockholders of record on Wednesday, November 26th were given a dividend of $0.12 per share. This represents a $0.48 annualized dividend and a dividend yield of 1.2%. The ex-dividend date was Wednesday, November 26th. Phibro Animal Health's dividend payout ratio (DPR) is 28.92%.

Wall Street Analyst Weigh In

Several research analysts recently commented on PAHC shares. JPMorgan Chase & Co. raised their price target on shares of Phibro Animal Health from $45.00 to $50.00 and gave the stock an "overweight" rating in a research note on Friday, November 7th. Zacks Research upgraded shares of Phibro Animal Health from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, December 9th. Finally, Weiss Ratings reaffirmed a "buy (b-)" rating on shares of Phibro Animal Health in a research note on Monday, December 29th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, two have given a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Hold" and an average price target of $31.40.

View Our Latest Stock Analysis on PAHC

Institutional Investors Weigh In On Phibro Animal Health

Several hedge funds have recently modified their holdings of the business. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of Phibro Animal Health by 28.7% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,544 shares of the company's stock valued at $319,000 after purchasing an additional 1,906 shares in the last quarter. Farther Finance Advisors LLC boosted its position in Phibro Animal Health by 113.2% during the 4th quarter. Farther Finance Advisors LLC now owns 727 shares of the company's stock valued at $27,000 after acquiring an additional 386 shares in the last quarter. Harbor Capital Advisors Inc. increased its holdings in shares of Phibro Animal Health by 15.5% in the 4th quarter. Harbor Capital Advisors Inc. now owns 12,230 shares of the company's stock valued at $457,000 after acquiring an additional 1,641 shares during the period. Balboa Wealth Partners raised its position in shares of Phibro Animal Health by 13.0% in the 4th quarter. Balboa Wealth Partners now owns 6,046 shares of the company's stock worth $226,000 after acquiring an additional 696 shares in the last quarter. Finally, Empirical Financial Services LLC d.b.a. Empirical Wealth Management lifted its stake in shares of Phibro Animal Health by 21.2% during the 4th quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 17,842 shares of the company's stock worth $667,000 after purchasing an additional 3,122 shares during the last quarter. Hedge funds and other institutional investors own 99.34% of the company's stock.

Phibro Animal Health Company Profile

(Get Free Report)

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro's portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.